相关实验视频

Updated: Jul 27, 2025

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

对于NLRP3炎症酶诱导的乳腺癌,可能的治疗点

Xixi Wang¹, Junyi Lin^2,3, Zhe Wang¹

¹Department of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, China.

Discover oncology

|June 10, 2023

概括

炎症驱动乳腺癌 (BC) 的进展. 炎症的关键调节者NLRP3炎症体在BC中起着复杂的作用,并呈现出治疗点.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

炎症是乳腺癌 (BC) 发展的组成部分,影响了扩散,入侵,血管新生和转移.
瘤微环境 (TME) 利用细胞因子释放,由炎症性卡斯帕和模式识别受体介导,以驱动瘤发生.
诺德类受体蛋白3 (NLRP3) 炎症体是炎症的关键调节者,与包括癌症在内的各种疾病有关.

研究的目的:

审查NLRP3炎症体的结构,生物特征和机制.
阐明NLRP3在乳腺癌中的多方面的作用,包括其与非编码RNA和TME的相互作用.
探索针对NLRP3炎症酶的治疗策略,以治疗乳腺癌,特别是三阴性乳腺癌 (TNBC).

主要方法:

文献综述侧重于NLRP3炎症酶的结构,功能及其在乳腺癌中的作用.
对NLRP3炎症酶激活及其与乳腺癌进展和抑制的联系进行现有研究的分析.
检查治疗方法,包括纳米粒子技术和基因疗法,针对乳腺癌模型中的NLRP3.

主要成果:

NLRP3炎症酶激活与炎症性疾病有关,并且在瘤发生过程中表现出双重作用,根据背景可能抑制或促进癌症.
在乳腺癌中NLRP3炎症酶的参与是复杂的,与非编码RNA,microRNA和乳腺癌微环境的特定关联.
新兴的治疗策略利用NLRP3炎症酶调制来治疗潜在的乳腺癌,特别是在TNBC.

结论:

NLRP3炎症酶是乳腺癌发病和进展的重要因素.
了解NLRP3在乳腺癌TME中的复杂作用及其与非编码RNA的相互作用对于向治疗至关重要.
准NLRP3炎症酶为新型乳腺癌治疗策略提供了有前途的途径,特别是TNBC.

关键词:

乳腺癌是什么? 乳腺癌是什么基因治疗是一种基因疗法.在炎症中,一些细胞会发炎.在NLRP3中,NLRP3是NLRP3中的一个.纳米颗粒纳米颗粒

更多相关视频

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

Evaluation of Caspase Activation to Assess Innate Immune Cell Death

Evaluation of Caspase Activation to Assess Innate Immune Cell Death

Published on: January 20, 2023

相关概念视频

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

NF-κB-dependent Signaling Pathway

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...